在巨大肝细胞癌（HCC）的转化治疗中，腹腔镜门静脉结扎（PVL）后肝动脉灌注化疗（HAIC）联合抗PD-1免疫治疗和酪氨酸激酶抑制剂（TKI）极为罕见。这是一种结合了手术和肿瘤学的双重转换疗法。在此，我们报道两例双转化治疗后成功完成手术的病例。我们报道一名54岁男性和一名69岁女性被诊断为原发性HCC合并乙型肝炎肝硬化（病例2还合并脂肪肝）。肝脏）进行体检。由于术前评估残余肝脏体积不足，遂行腹腔镜右侧PVL，随后HAIC联合抗PD-1免疫治疗和TKI。最终顺利完成手术切除，病理证实一例肿瘤大部分坏死（90%），另一例未发现活体肿瘤组织。在手术改造过程中，我们的治疗方案考虑到了同时控制和改造肿瘤，有望为根治性肝切除提供更多机会，改善大型肝癌患者的预后。©作者2023。百事登出版集团版权所有。

In the translational therapy of giant hepatocellular carcinoma (HCC), hepatic arterial infusion chemotherapy (HAIC) combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors (TKI) after laparoscopic portal vein ligation (PVL) is extremely rare. This is a dual conversion therapy that combines surgery and oncology. Here, we report two cases of successful surgical completion after dual conversion therapy.We report that a 54-year-old man and a 69-year-old woman were diagnosed with primary HCC combined with hepatitis B cirrhosis (case 2 also combined with fatty liver) on physical examination. Due to the insufficient residual liver volume assessed before surgery, laparoscopic right PVL was performed, followed by HAIC combined with anti-PD-1 immunotherapy and TKI. Finally, surgical resection was successfully completed, and pathology confirmed that the tumor was mostly necrotic (90%) in one case, and no live tumor tissue was found in the other case.In the process of surgical transformation, our treatment plan takes into account the control and transformation of oncology at the same time, which is expected to provide more opportunities for radical hepatectomy and improve the prognosis of patients with large liver cancer.©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.